Safety data on GRNOPC1

Safety data to data form the trial has shown:

1.No surgical complications during or after the procedures.
2.No adverse events related to the injection procedures or to GRNOPC1.
3.A few mild adverse events related to tacrolimus.
4.No evidence of cavitation in the spinal cord at the injury sites on MRI.
5.No unexpected neurological changes.
6.No evidence of immune responses to GRNOPC1.

GRNOPC1 was delivered to four spinal cord injured patients at a dose of two million cells without complications from either the cells or the surgical procedure itself, and without any negative effects on the spinal cord or neurological function of the patients to date. The only side-effects observed were due to the immunosuppressive drug tacrolimus, which is administered for the first two months after injection of GRNOPC1. Furthermore, there is no evidence to date of immune rejection of GRNOPC1, an allogeneic cell therapy, including after withdrawal of immunosuppressive drug.
The facts all point to success. We know that these stem cells work. The big question is whether they are safe. We have shown that to date.  Geron is positioned for huge increases from this and Oncology programs. Then orchestrated takeover bid most likely scenario, as any review of the new CEO will indicate. Those are the facts.  Stock moves up. Market as well.


Good luck in this rigged casino,